AU Patent

AU701578B2 — Immunoglobulins devoid of light chains

Assigned to Vrije Universiteit Brussel VUB · Expires 1999-02-04 · 27y expired

What this patent protects

The invention relates to an immunoglobulin characterized in that it comprises two heavy polypeptide chains sufficient for the formation of a complete antigen binding site or several antigen binding sites, this immunoglobulin being further devoid of light polypeptide chains.

USPTO Abstract

The invention relates to an immunoglobulin characterized in that it comprises two heavy polypeptide chains sufficient for the formation of a complete antigen binding site or several antigen binding sites, this immunoglobulin being further devoid of light polypeptide chains.

Drugs covered by this patent

dabigatran-etexilate-mesylate (DABIGATRAN ETEXILATE MESYLATE)

Patent Metadata

Patent number: AU701578B2
Jurisdiction: AU
Classification: —
Expires: 1999-02-04
Drug substance claim: No
Drug product claim: No
Assignee: Vrije Universiteit Brussel VUB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.